BioWin

Accelerating Belgian health-tech & biopharma innovation

[BioWin @BioWin_asbl]

Bio-Sourcing and Zerion Pharma have obtained a €1.3 million EU grant reward under the Eurostars program to advance an orally administered anti‑HER2 antibody Trastuzimab, for treatment of breast cancer. https://t.co/vtddOHcWQe

[BioWin @BioWin_asbl]

Belgium bypasses EU approval for innovative life-saving therapies. https://t.co/2WIHAiXuRV

[BioWin @BioWin_asbl]

Neuvasq Biotechnologies appoints Denis Bedoret as Executive Director https://t.co/zBFM0oscF8

[BioWin @BioWin_asbl]

Full-Life Technologies announces US$77 million financing to accelerate the development of its radiopharmaceutical pipeline worldwide and manufacturing capabilities in Belgium. https://t.co/X8I2cbybW9

[BioWin @BioWin_asbl]

KiOmed Pharma’s innovative osteoarthritis solution, KioMedine-vs-one, has officially been approved by the Chinese FDA, bringing treatment to 100 million patients. https://t.co/9nSVz6mNdV

[BioWin @BioWin_asbl]

BiOkuris Announces Positive Results from Pivotal IBS Study (Vitabiotic) Evaluating BK002 Synbiotic formulation demonstrates dual therapeutic effect on gastrointestinal symptoms and anxiousness. https://t.co/7L9ECuNzli

[BioWin @BioWin_asbl]

Hyloris Pharmaceuticals announces positive clinical study results for atomoxetine oral solution. https://t.co/yjCv9WM1iS

[BioWin @BioWin_asbl]

@endotools Therapeutics and Fujifilm Middle East FZE partner to extend access to innovative treatments for obesity. https://t.co/t76arlXkEN

[BioWin @BioWin_asbl]

Kaneka @Eurogentec completes commercial mRNA GMP facility expansion. https://t.co/gxYwnDxVyI

[BioWin @BioWin_asbl]

Hyloris Partners with Kuvatris Therapeutics to Advance Suramin IV Development for Sleeping Sickness, Targeting a Priority Review Voucher. https://t.co/pk36yA9Bwx

[BioWin @BioWin_asbl]

Novadip Biosciences received RMAT designation for NVD003, its regenerative treatment for congenital pseudarthosis of the tibia. https://t.co/04ncZrOi8l

[BioWin @BioWin_asbl]

UCB announces major U.S. investment to expand biologics manufacturing capacity. @ucb_news https://t.co/EFgifXNUE6

[BioWin @BioWin_asbl]

ATB Therapeutics Announces Appointment of Dr. Torsten Dreier as Chief Development Officer and Opening of New R&D Hub in Gent. https://t.co/lLeMFwh6WK

[BioWin @BioWin_asbl]

For the first time in Belgium, two patients suffering from sarcomas, rare cancers that affect bone or soft tissue, have undergone surgery using augmented reality. https://t.co/t16XKURXEW

[BioWin @BioWin_asbl]

Rystiggo (rozanolixizumab) receives approval in Japan for two new administration methods as UCB begins ONWARD program for patient support. https://t.co/1QeoBq6GjB

[BioWin @BioWin_asbl]

Do you have an innovative idea in health and need the right partners to bring it to life? If your project fits within one of BioWin’s strategic themes - #biopharma or #healthtech - then you may be eligible for funding. https://t.co/Eq0PnRuTXp

[BioWin @BioWin_asbl]

One more step for AbolerIS Pharma! The biotech has just dosed the first participants in a Phase 1 trial for ABO21009, a first-in-class anti-CD45RC monoclonal antibody for rheumatoid arthritis. https://t.co/MzHR0iYfTY

[BioWin @BioWin_asbl]

@bioxodes announces positive Phase 2a interim data for BIOX-101 in intracerebral hemorrhagic stroke patients. https://t.co/rm3iGsSnKW

[BioWin @BioWin_asbl]

Aptissen and kiOmed Pharma forge a strategic alliance bringing breakthrough in Osteoarthritis Treatment. https://t.co/qRmG44Uqba

[BioWin @BioWin_asbl]

@CuriumPharma, a nuclear medicine company, has acquired Nucleis, a specialist in GMP manufacturing and distribution of PET radiopharmaceutical drugs.
https://t.co/MGPZ7sOz5b